A report by the Government Accountability Office says the FDA is too slow in picking up and responding to safety issues of drugs already on the market. The FDA also lacks clear policies for dealing with drug safety issues and often fails to include its best safety experts in important meetings, the report found. The GAO suggested Congress widen FDA's authority to require drug companies to conduct studies of drugs on the market.

Related Summaries